Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07063745 · ClinicalTrials.gov registry record · Phase 2
A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
A Phase 2 study of Metastatic Non-small Cell Lung Cancer With MTAP Deletion, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 590
- Enrollment target
- 20
- Study locations
NCT07063745: Recruiting Phase 2 study of Metastatic Non-small Cell Lung Cancer With MTAP Deletion, sponsored by Bristol-Myers Squibb.
NCT07063745 is a Phase 2 study of Metastatic Non-small Cell Lung Cancer With MTAP Deletion that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 590 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (344% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07063745, a Phase 2 study of Metastatic Non-small Cell Lung Cancer With MTAP Deletion, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 590 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion
Primary Outcome
Phase 2
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Cisplatin
- OTHER Placebo
- DRUG BMS-986504
Study Locations (20)
Florida
- Local Institution - 0152 - Fort Lauderdale
- Mayo Clinic in Florida - Jacksonville
- Local Institution - 0430 - St. Petersburg
Michigan
- Local Institution - 0418 - Ann Arbor
- Local Institution - 0405 - Detroit
- Local Institution - 0420 - Traverse City
Arizona
- Mayo Clinic in Arizona - Phoenix - Phoenix
- Local Institution - 0120 - Tucson
California
- USC/Norris Comprehensive Cancer Center - Los Angeles
- Local Institution - 0444 - Los Angeles
Kentucky
- Baptist Health Lexington - Lexington
- University of Kentucky Chandler Medical Center - Lexington
Alaska
- Alaska Oncology and Hematology - Anchorage
Arkansas
- Highlands Oncology Group - Springdale
Idaho
- St. Luke's Cancer Institute: Boise - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 590 participants |
| Start Date | 2026-01-02 |
| Est. Completion | 2031-08-12 |
| Phase | Phase 2 |
What NCT07063745 shows while recruiting
NCT07063745 is an interventional study that assigns participants to a tested intervention. The registered 590 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (344% higher).
The record links to 1 condition, with Metastatic Non-small Cell Lung Cancer With MTAP Deletion appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT07063745 names 20 study sites across 13 states, led by Florida, Michigan, Arizona.
Frequently Asked Questions
What is clinical trial NCT07063745 about?
NCT07063745 is a clinical study titled "A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion". The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with ...
What is the current status of trial NCT07063745?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 590 participants. The study started on 2026-01-02. Estimated completion is 2031-08-12.
What conditions does trial NCT07063745 study?
This clinical trial studies the following conditions: Metastatic Non-small Cell Lung Cancer With MTAP Deletion.
What interventions are being tested in trial NCT07063745?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Cisplatin (DRUG), Placebo (OTHER), BMS-986504 (DRUG).
Who is sponsoring clinical trial NCT07063745?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07063745 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07063745's enrollment target sits among peer trials
590 58th of 2000 higher than 1,943 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01365169 · 590 participants · NA
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
- NCT03774758 · 590 participants
Biomarkers for Risk Stratification in Lung Cancer
- NCT04747626 · 590 participants · NA
B-SAFER: Branched Stented Anastomosis Frozen Elephant Trunk Repair
- NCT05722938 · 590 participants · Phase 3
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI